Cybin initiates dosing of final cohort of its phase 2 trial of cyb003 in major depressive disorder

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that it has initiated dosing in cohort 6, the final cohort of its phase 2 study evaluating cyb003, an investigational deuterated analog of psilocybin for the potential treatment of major depressive disorder (“mdd”). the first.
CYBN Ratings Summary
CYBN Quant Ranking